Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01954628
Registration number
NCT01954628
Ethics application status
Date submitted
21/09/2013
Date registered
7/10/2013
Date last updated
12/06/2017
Titles & IDs
Public title
Efficacy and Safety of AQX-1125 in Unstable COPD
Query!
Scientific title
The FLAGSHIP Study: A 12-week Phase II Study to Evaluate the Efficacy and Safety of AQX-1125 Following Exacerbations in Patients With Chronic Obstructive Pulmonary Disease (COPD) by Targeting the SHIP1 Pathway
Query!
Secondary ID [1]
0
0
AQX-1125-202
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
FLAGSHIP
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
COPD
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Chronic obstructive pulmonary disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - AQX-1125
Treatment: Drugs - Placebo
Experimental: AQX-1125 - 1 x AQX-1125 capsule daily
Placebo Comparator: Placebo - 1 x Placebo capsule daily
Treatment: Drugs: AQX-1125
Synthetic SHIP1 activator
Treatment: Drugs: Placebo
Placebo control
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
The Primary Efficacy Variable Was the AAC for Daily EXACT Scores During the 12-week Treatment Period.
Query!
Assessment method [1]
0
0
The primary variable (endpoint) of this study is the difference in the Area Above the Curve (AAC) for the daily EXACT score from baseline to Week 12 between subjects treated with AQX-1125 and placebo.The EXACT questionnaire is a patient reported outcome (PRO) measure designed to standardise the method for evaluating the frequency, severity and duration of acute exacerbations of COPD. The EXACT is a 14-item daily questionnaire where each item is assessed on a 5 or 6 point ordinal scale. Participants completed the EXACT questionnaire on a daily basis via an electronic diary from Day 1 (pre-dose) to Day 84 (week 12). Higher scores on the daily EXACT questionnaire indicate a more severe health state. When the post-treatment EXACT scores are lower (i.e. improved symptoms) than baseline EXACT, the AACs are positive.
Query!
Timepoint [1]
0
0
12 weeks
Query!
Secondary outcome [1]
0
0
Change From Baseline in COPD Assessment Tool (CAT) Score
Query!
Assessment method [1]
0
0
The secondary objective is to evaluate the treatment effect of once daily administrations of AQX-1125 compared to placebo over 12 weeks on the COPD Assessment Tool (CAT) score.The CAT questionnaire measures the impact of COPD on wellbeing and daily life. Participants answer 8 questions on a scale from 0 (best) to 5 (worst). The total score ranges from 0 to 40 with higher scores indicating more impact. A negative change from baseline indicates improvement. The change in total CAT score from Day 1, before taking study drug (baseline), to end of the 12 week treatment period was compared between the two treatments using an ANOVA model adjusting for treatment and region and including the baseline score as a covariate.
Query!
Timepoint [1]
0
0
12 weeks
Query!
Secondary outcome [2]
0
0
Analysis of the Number of COPD Exacerbations (Medically Treated Event (MTE))
Query!
Assessment method [2]
0
0
The secondary objective is to evaluate the treatment effect of once daily administrations of AQX-1125 compared to placebo over 12 weeks on the number of COPD exacerbations (MTE).
COPD exacerbations were referred to as Medically Treated Exacerbations (MTEs) and identified as a change in symptoms and/or signs of COPD requiring prescription of one or both of: (1) Course of oral corticosteroids or (2) Antibiotic(s).
Query!
Timepoint [2]
0
0
12 weeks
Query!
Secondary outcome [3]
0
0
Time to First COPD Exacerbation
Query!
Assessment method [3]
0
0
The secondary objective is to evaluate the treatment effect of once daily administrations of AQX-1125 compared to placebo over 12 weeks on the time to first exacerbation requiring medical intervention of oral corticosteroids and/or antibiotics.
Query!
Timepoint [3]
0
0
12 weeks
Query!
Secondary outcome [4]
0
0
The Number of Subjects With at Least One COPD Exacerbation.
Query!
Assessment method [4]
0
0
The number of subjects that presented with a COPD exacerbation during the 12 week treatment period.
Query!
Timepoint [4]
0
0
12 weeks
Query!
Secondary outcome [5]
0
0
Change From Baseline in FEV1
Query!
Assessment method [5]
0
0
The secondary objective is to evaluate the treatment effect of once daily administrations of AQX-1125 compared to placebo over 12 weeks on forced expiratory volume in 1 second [FEV1].
FEV1 was determined from post-bronchodilator spirometry testing done at clinic visits.
Query!
Timepoint [5]
0
0
12 weeks
Query!
Secondary outcome [6]
0
0
AQX-1125 Concentrations in Plasma (Trough Values)
Query!
Assessment method [6]
0
0
The secondary objectives are to evaluate the pharmacokinetics (PK) of AQX-1125 in plasma.
Query!
Timepoint [6]
0
0
12 weeks
Query!
Eligibility
Key inclusion criteria
1. Male or female aged =40 years at screening
2. History of COPD for at least 18 months prior to screening, characterised by excessive
sputum production
3. Chronic productive cough for at least 3 months in each of the 2 years prior to
screening (if other causes of productive cough have been excluded) and/or an
exacerbation of COPD with predominantly bronchitic symptoms at enrolment
4. At least 2 documented exacerbations during the last 18 months prior to screening.
5. Presentation of a diagnosed acute exacerbation of COPD, or have recently (within 3
days) been discharged from hospital due to an acute exacerbation of COPD
6. Ability to perform pulmonary function testing and with documented fixed airway
obstruction determined by an FEV1 /FVC [forced vital capacity] ratio
(post-bronchodilator) of <0.70 and a predicted FEV1 value of 30%-80% of normal within
the 6 months prior to Visit 1.
7. Former smoker or current smoker, both with a smoking history of at least 10 pack years
Query!
Minimum age
40
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Diagnosis of other relevant lung disease (e.g. asthma, cystic fibrosis [CF] or
significant non-CF bronchiectasis)
2. Known alpha-1-antitrypsin deficiency
3. Treatment with roflumilast or theophylline within 1 month prior to screening
4. Lobar pneumonia, with current positive chest X-ray (CXR) or within the 3 months prior
to screening including the presence of any new radiological infiltrate on CXR within
the previous two weeks
5. Hospitalisation for more than 7 days for current acute exacerbation, or the
requirement for intubation during hospitalisation
6. For outpatients, prior medical history indicating that previous exacerbations required
>3 weeks to stabilise
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/10/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/12/2015
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
400
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
0
0
Department of Respiratory & Sleep Medicine, Westmead Hospital - Wentworthville
Query!
Recruitment postcode(s) [1]
0
0
2145 - Wentworthville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Ohio
Query!
Country [2]
0
0
Denmark
Query!
State/province [2]
0
0
Odense
Query!
Country [3]
0
0
Finland
Query!
State/province [3]
0
0
Helsinki
Query!
Country [4]
0
0
Hungary
Query!
State/province [4]
0
0
Deszk
Query!
Country [5]
0
0
New Zealand
Query!
State/province [5]
0
0
Wellington
Query!
Country [6]
0
0
Poland
Query!
State/province [6]
0
0
Lodz
Query!
Country [7]
0
0
Sweden
Query!
State/province [7]
0
0
Lund
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Aquinox Pharmaceuticals (Canada) Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objective of this study is to evaluate the effect of 12 weeks of treatment with
once daily administration of AQX-1125 compared to placebo in subjects following exacerbations
of Chronic Obstructive Pulmonary Disease (COPD) by targeting the SHIP1 (Src Homology
2-containing Inositol-5'-Phosphatase 1) pathway.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01954628
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Stephen B Shrewsbury, MD
Query!
Address
0
0
Aquinox Pharmaceuticals (Canada) Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01954628
Download to PDF